Looking ahead to 2030, our model projects CRWD could trade at an average price of $1,594.52, with a potential range between $1,195.89 and $1,993.15. This represents a potential 685.2% return from ...

Looking ahead to 2030, our model projects CMCSA could trade at an average price of $47.65, with a potential range between $35.73 and $59.56. This represents a potential 100.3% return from today's ...

“Market fundamentals are strong and well supported, with higher margins and earnings momentum catalyzed by new technology. The scale and depth of our client relationships globally have never been ...

“I am honored to step into the role of CEO and energized by the opportunities ahead. Conagra has an exceptional portfolio of iconic brands, talented employees, strong customer relationships, and ...

Looking ahead to 2030, our model projects AEM could trade at an average price of $221.24, with a potential range between $165.93 and $276.55. This represents a potential 61.5% return from today's ...

Novartis (NVS) Q1 2026 earnings: EPS $1.99 vs $2.07 est. (MISS by 3.7%). Revenue $13.11B vs $13.48B est. View earnings history, market reaction charts, and AI analysis.

“We delivered a record quarter with broad-based strength across Distribution and Hyve, building on the momentum we have carried out of recent quarters. Our results reflect consistent execution against ...

“We are reinforcing our core strengths, unlocking new growth drivers, and building for the long term. In the first quarter, our hit drama lineup drove sequential membership revenue growth and cemented ...

Levi Strauss raised its full-year fiscal 2026 guidance across all key metrics. Reported net revenues growth is now expected at 7.0% to 7.5% (up from 5.5% to 6.5%), organic net revenues growth at 5.5% ...